Pfizer Inc. (PFE)

42.52
0.63 1.50
NYSE : Health Technology
Prev Close 41.89
Open 42.20
Day Low/High 42.13 / 42.70
52 Wk Low/High 34.32 / 46.47
Volume 7.92M
Avg Volume 25.91M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 232.34B
EPS 1.90
P/E Ratio 22.29
Div & Yield 1.44 (3.26%)
REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

For Pfizer, China is third largest market and a growing area of concern.

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

We believe the company has double-digit total return potential at its current price.

Dow Slumps on Trump Trade War Escalation

Dow Slumps on Trump Trade War Escalation

The Dow tumbled Wednesday, losing ground for the first session in five, after the U.S. threatened additional tariffs on $200 billion worth of China-made goods.

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer reorganization could pave way for the company to spin off businesses.

Jim Cramer Reacts to Pfizer's Reorganization

Jim Cramer Reacts to Pfizer's Reorganization

Pfizer announced plans Wednesday to reorganize into three units.

Pfizer Doesn't Look Fundamentally or Technically Strong

Pfizer Doesn't Look Fundamentally or Technically Strong

The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

The changes will take effect at the start of 2019.

Jim Cramer: The Money Isn't Leaving the Casino

Jim Cramer: The Money Isn't Leaving the Casino

The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.

China Tariffs, Fox-Sky, Pfizer, Apple, Free Slurpees - 5 Things You Must Know

China Tariffs, Fox-Sky, Pfizer, Apple, Free Slurpees - 5 Things You Must Know

U.S. stock futures fall sharply on Wednesday, after the White House publishes a list of $200 billion worth of China-made goods it says will be hit with fresh tariffs; Twenty-First Century Fox increases its bid to buy Britain's Sky; Pfizer to 'defer' raising drug prices following talks with Donald Trump.

Pfizer Rolls Back Drug Price Hike Following Trump Talks

Pfizer Rolls Back Drug Price Hike Following Trump Talks

Pfizer bowed to pressure from President Donald Trump late Tuesday by agreeing to temporarily rollback a planned price increase following Tweets suggesting the group "should be ashamed".

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Here are the business stories you must know as U.S. stock futures fall sharply.

Pfizer To Organize For Future Growth

Pfizer To Organize For Future Growth

Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an...

Pfizer's Announces It Will Defer Company's Price Increases

Pfizer's Announces It Will Defer Company's Price Increases

Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the company's price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to...

Trump Blasts Pfizer for High Drug Prices in Tweet, but Stock Still Rises

Trump Blasts Pfizer for High Drug Prices in Tweet, but Stock Still Rises

President Trump criticized Pfizer and others in a tweet on July 9, saying they hiked prices 'for no reason.'

How to Play Pfizer's Fresh Upside Breakout

How to Play Pfizer's Fresh Upside Breakout

A bullish strategy for traders of PFE stock.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Pfizer Hikes Drug Prices Again, Despite President Trump's Promises

Pfizer Hikes Drug Prices Again, Despite President Trump's Promises

While President Trump pledged last month that pharma companies would decide to voluntarily aggress to 'massive' drops in drug prices, clearly nobody told Pfizer.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Monday 7/2/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Monday 7/2/18)

Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorisation In The European Union For Active Psoriatic Arthritis

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorisation In The European Union For Active Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who...

Pfizer Declares 34-Cent Third-Quarter 2018 Dividend

Pfizer Declares 34-Cent Third-Quarter 2018 Dividend

The board of directors of Pfizer Inc. today declared a 34-cent third-quarter 2018 dividend on the company's common stock, payable September 4, 2018, to shareholders of record at the close of business on August 3, 2018.

Pfizer Announces Overall Survival Results From Phase 3 PALOMA-3 Trial Of IBRANCE® (Palbociclib) In HR , HER2- Metastatic Breast Cancer

Pfizer Announces Overall Survival Results From Phase 3 PALOMA-3 Trial Of IBRANCE® (Palbociclib) In HR , HER2- Metastatic Breast Cancer

Pfizer today announced overall survival (OS) results from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE ® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human...

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.

Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

Is Goldman Sachs Going to Be the Next Allergan?

Is Goldman Sachs Going to Be the Next Allergan?

Don't count on it. The fundamentals paint two very different pictures, Cramer says.

Pfizer Announces Extension Of Zithromax® Antibiotic Donation Program Through 2025 To Help Eliminate World's Leading Infectious Cause Of Blindness

Pfizer Announces Extension Of Zithromax® Antibiotic Donation Program Through 2025 To Help Eliminate World's Leading Infectious Cause Of Blindness

Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of...

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

Senate Panel Considers Bill Aimed at Getting Generic Drugs to Market Faster

A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.

TheStreet Quant Rating: B (Buy)